| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaid expenses and other current assets | 19,138 | |||
| Other receivable | 8,105 | |||
| Marketable securities | 298,085 | |||
| Cash and cash equivalents | 67,487 | |||
| Collaboration receivable - related party | 16,270 | |||
| Total current assets | 409,085 | |||
| Restricted cash | 1,450 | |||
| Property and equipment, net | 674 | |||
| Other long-term assets | 1,756 | |||
| Right-of-use operating asset | 9,957 | |||
| Total assets | 422,922 | |||
| Accrued expenses | 42,072 | |||
| Operating lease liability, current portion | 1,878 | |||
| Accounts payable | 692 | |||
| Total current liabilities | 44,642 | |||
| Operating lease liability, net of current portion | 9,543 | |||
| Total liabilities | 54,185 | |||
| Treasury stock, at cost, 3,033 shares at june 30, 2025 and december 31, 2024 | 400 | |||
| Accumulated deficit | -3,082,191 | |||
| Common stock, 0.0001 par value per share 120,000,000 shares authorized at june 30, 2025 and december 31, 2024 62,631,252 and 61,359,242 shares issued at june 30, 2025 and december 31, 2024, respectively 62,628,219 and 61,356,209 shares outstanding at june 30, 2025 and december 31, 2024, respectively | 6 | |||
| Additional paid-in capital | 3,451,307 | |||
| Accumulated other comprehensive income | 15 | |||
| Total stockholders equity | 368,737 | |||
| Total liabilities and stockholders equity | 422,922 | |||
Sage Therapeutics, Inc. (SAGE)
Sage Therapeutics, Inc. (SAGE)